r e v i e w nature medicine VOLUME 19 | NUMBER 7 | JULY 2013 8 5 9
HBV and HCV are both parenterally transmitted, enveloped viruses that have multiple genotypes. Despite different replication strategies and life cycles, both viruses have developed highly successful ways to establish chronic hepatitis (reviewed in refs. 1-3), resulting in 350 million chronic HBV infections and 130-170 million chronic HCV infections worldwide. About one million people die from the sequelae of chronic HBV and HCV infections each year, mostly as a result of end-stage liver disease and liver cancer.
Disease progression to cirrhosis is nonlinear, and large fluctuations in viral titer and disease activity in particular are observed in HBVinfected patients over time (Box 1, Fig. 1 ). Whereas the viral titer is generally more consistent and the disease activity lower in chronic HCV infection than in HBV infection, there is still considerable variation in both parameters among HCV-infected patients. Liver injury and disease progression are thought to be driven by host immune responses in both infections [1] [2] [3] , and previous research has mostly focused on the role of virus-specific T cells in this process. Virus-specific CD8 + T cells are recognized as the main effector cells, and their experimental depletion delays the clearance of acute HBV 4 and HCV 5 infection in chimpanzees. Work over the past 5 years revealed multiple, nonredundant mechanisms that drive attenuation and exhaustion of HBV-and HCV-specific T cells in chronically infected patients [6] [7] [8] [9] [10] [11] . The few virus-specific T cells that remain tend to target sequences at which the virus has mutated and, thus, cannot eliminate infected target cells [12] [13] [14] [15] [16] . Given these observations, it is plausible that most of the immune-mediated liver injury in chronic HBV and HCV infection is mediated by immune cells other than virus-specific T cells.
This review covers virus and host mechanisms that downregulate effector functions of antigen-specific T cells in the liver and examines the role of antigen-nonspecific inflammatory cells, in particular natural killer (NK) cells in the pathogenesis of chronic viral hepatitis and regulation of inflammation.
T cell responses in chronic viral hepatitis Strong CD4 + helper and CD8 + effector T cell responses have been observed in patients [17] [18] [19] and experimentally infected chimpanzees 4, 5, 20 that clear HBV and HCV infection. In HCV infection, protective immunity is more likely in the presence of HLA-B27, HLA-B57 and HLA-A3 alleles. Protective T cell responses tend to target epitopes that do not allow escape mutations because of high costs to viral replicative fitness [21] [22] [23] .
Whereas neutralizing antibodies are an important component of protective immunity against HBV 19 , they are not required to clear HCV, as demonstrated in patients with hypogammaglobulinemia 24 , and their titer decreases to undetectable levels long term after HCV clearance 25 . Broad neutralizing antibody responses appear only after chronic HCV infection is established-they are unable to clear the infection at this stage and select viral escape mutants 26 .
Although the immunological mechanisms for viral persistence differ for HBV and HCV (Box 2), a common feature is the downregulation of virus-specific T cell responses in the chronic phase, which is marked by progressive functional exhaustion and ultimately deletion of virus-specific CD4 + and CD8 + T cells 8, 9 . In addition, an inflammation-induced increase in regulatory T cell counts [27] [28] [29] , a decrease in intrahepatic arginine levels 30 and a shift in the ratio between T cell-sustaining cytokines such as interleukin-2 (IL-2) 31, 32 and suppressive cytokines such as IL-10 and transforming growth factor-β (TGF-β) [33] [34] [35] dampen the virus-specific T cell response of infected patients. Lastly, viral mutations in dominant T cell epitopes that have been selected as a means to establish chronic infection render the remaining T cell responses irrelevant (Box 2). These viral escape mutations have been described r e v i e w in both HBV-infected 12 and HCV-infected [14] [15] [16] 36 patients, but they are more frequent in HCV infection as a result of the high replicative fitness of HCV paired with the high error rate of its polymerase.
Prolonged exposure to viral antigens is the main cause for the reduced frequency and impaired effector function of virus-specific CD8 + T cells 37, 38 , as first revealed in mice infected with lymphocytic choriomeningitis virus (LCMV). LCMV is a noncytopathic arenavirus that is widely used as a model to study the pathogenesis of viral hepatitis given that HBV and HCV do not infect rodents. Consistent with findings in the LCMV model, CD8 + T cells that are not stimulated anymore owing to viral escape mutations do not show an exhausted phenotype in HCV-infected patients 39 . In HBV infection, chronic T cell stimulation may be caused by both viral peptides presented on the major histocompatibility complex (MHC) of infected cells and by viral antigens, such as soluble HBV surface antigen (HBsAg) and the extracellular form of HBcAg (HBeAg), that can access the MHC class I pathway for cross-presentation 40 . This is supported by a recent translational study that showed a smaller gain in HBV-specific T cell function in patients who, upon treatment, turned negative for HBV DNA but remained positive for HBsAg than in patients who turned negative for both HBV DNA and HBsAg 41 .
The downregulation of T cell responses follows a similar pattern in patients with HBV or HCV infection and in LCMV-infected mice. In all three infections, virus-specific T cells show increased expression of inhibitory molecules such as programmed death-1 (PD-1) 6, 8, 10, [42] [43] [44] ,
Box 1 Natural history of chronic hepatitis
Chronic HBV infection Chronic HBV infection results mostly from vertical transmission from mother to neonate. HBV-infected neonates and children typically experience an immunotolerant phase with normal ALT levels despite high levels of circulating HBV DNA and HBe antigen, the secreted form of the HBV core antigen. This phase may last for decades and eventually transitions into an immunoactive phase with more severe liver disease and fluctuations in HBV titer (Fig. 1a) . Whereas an extended immunoactive phase is associated with rapid disease progression and liver cirrhosis, it may also convert into a low replicative phase with reduced inflammation, low HBV titers <2,000 IU ml −1 , and conversion to HBeAg − and anti-HBe + status (HBe antigen undetectable and antibodies to HBe antigen detectable in the blood). A subset of patients later develops recurrent necroinflammatory liver disease with high-level replication of either wild-type HBeAg + HBV or mutant HBeAg − HBV (reviewed in refs. 3, 140) . Older age, male gender, alcohol consumption and HIV co-infection increase the risk for an adverse outcome of HBV infection.
Even though HBV infection can be prevented by a vaccine, there is still no curative treatment for most individuals who are already chronically infected. Cure is defined as clearance of HBsAg and seroconversion to anti-HBs + status (antibodies to HBs antigen detectable in the blood), which occurs spontaneously in about 1% of chronically infected patients per year. IFN-based therapies achieve this goal in <10% of treated patients (reviewed in ref. 141 ). Therapy with nucleoside or nucleotide analogs decreases the HBV titer but results in viral resistance 141 because it does not eliminate covalently closed circular HBV DNA, the transcriptional template of HBV.
In contrast to vertical HBV transmission during the neonatal period, horizontal transmission during adulthood causes acute hepatitis, which is resolved by more than 95% of infected adults and results in lifelong T cell-and antibody-mediated immunity. The small percentage of individuals who progress to chronic infection typically do not experience a long immunotolerant phase and enter the immunoactive phase of chronic hepatitis sooner than after vertical transmission.
Chronic HCV infection
Chronic HCV infection is typically acquired during adulthood and about 70-85% of infected persons develop viral persistence. Chronic hepatitis is characterized by relatively mild liver inflammation without significant fluctuations in HCV RNA titers. Disease progression is accelerated with greater age, obesity, alcohol consumption and HIV co-infection (Fig. 1b) . IFN-and ribavirin-based therapy is less effective in the chronic phase than in the acute phase of hepatitis, but the directly acting antivirals recently approved by the US Food and Drug Administration have significantly improved treatment responses 142 .
Both hepatitis B and C are also associated with extrahepatic disease manifestations, which can be mediated by virus-specific immune complex injury and include arthritis, vasculitis and glomerulonephritis. In addition, mono-and polyclonal B cell expansions have been observed in chronic hepatitis C and can evolve into mixed cryoglobulinemia and B cell malignancies such as non-Hodgkin's lymphoma (reviewed in ref. 143 ).
ALT and viremia levels
Immunotolerance phase
Hepatitis C
Time after infection during adulthood (weeks) 10, 53 . Overall, T cell exhaustion follows a predictable pattern, as first shown in mice with LCMV hepatitis (reviewed in ref. 54) . T cells that undergo exhaustion in this model first lose their capacity to produce IL-2, a cytokine that supports proliferation. IL-2 is predominantly produced by CD4 + T cells, whereas CD8 + T cells produce little IL-2 themselves and depend on CD4 + T cell help. This is followed by sequential loss of cytotoxicity and TNF-α and IFN-γ production. In addition, the intracellular expression of proapoptotic proteins such as Bcl2-interacting mediator (Bim) increases in virus-specific CD8 + T cells of LCMV-infected mice 55 , as well as in those of HBV-or HCV-infected patients 56, 57 .
From a therapeutic angle, the blockade of these inhibitory pathways along with selective stimulation of co-stimulatory pathways is being pursued both in vitro and in vivo as a means to rescue exhausted T cells and to restore their function. The most effective strategy depends on the etiology of viral hepatitis. For example, PD-L1 blockade combined with CD137 co-stimulation has been shown to reverse the exhaustion of virus-specific CD8 + T cells from patients with chronic HBV infection in vitro 58 . CD137 co-stimulation results in downregulation of Bim and upregulation of Bcl-2 family members, thus supporting survival of activated virus-specific T cells 58 . However, the same strategy does not reverse the dysfunction of virus-specific T cells in chronic HCV infection, even though they are less impaired in their capacity to produce IFN-γ and IL-2 than HBV-specific T cells 58 . Rather, functional recovery of HCV-specific T cells requires a combined CTLA-4 and PD-1-PD-L1 blockade 43, 59 . Finally, PD-1-PD-L1 blockade alone is sufficient to rescue virus-specific T cells in LCMV-infected mice 44 . Thus, the therapeutic blockade of the inhibitory pathways needs to be tailored to the specific viral infection.
In addition, there is a general antigen-nonspecific suppression of the effector phase of the intrahepatic immune response. Decreased arginine levels may contribute to this dysfunction, because arginine deprivation triggers T cell receptor (TCR)-CD3ζ downregulation, impaired T cell proliferation and reduced IL-2 production, as shown in HBV-infected patients 30 . Accordingly, addition of arginine rescues these T cell responses in vitro 30 . Second, an increased frequency of CD4 + T cells with regulatory function (Foxp3 + regulatory T cells) has been observed in the blood and in the liver of HBV-infected 27, 28 and HCV-infected 29 patients. Regulatory T cells proliferate in viral hepatitis because they have fewer T cell receptor excision circles in chimpanzees with chronic HCV infection than in HCV-naive chimpanzees 60 .
Finally, a higher level of expression of the immunosuppressive cytokine IL-10 has been observed in both blood and liver of HBVinfected 61 and HCV-infected 34 patients compared with that observed in uninfected controls. IL-10 is produced by regulatory T and B cells 33 , monocytes 62 and intrahepatic T cells 34 as shown in studies of HBV-infected and HCV-infected patients and by Kupffer cells from human livers 63 . IL-10 inhibits IFN-α production 62 and promotes apoptosis of human plasmacytoid dendritic cells 64 . It also inhibits antigen-presenting cells and attenuates the induction of antigenspecific CD8 + T cells in humans 65 . Although the frequency of dendritic cells has generally been reported to be low in the blood and high in the liver in patients with chronic HBV and HCV infection, there is no consensus on their functionality (reviewed in ref. 66 ). The lack of generalized immune suppression in patients with established chronic HCV infection argues for an antigen-specific immune
Box 2 Virus and host factors that result in HBV and HCV persistence
As outlined in Box 1, most chronic HBV infections are caused by vertical transmission from mother to child either in utero or during early infancy. On the basis of studies in rodent models, the immaturity of the neonatal immune system 144 , a tolerogenic effect of HBeAg in utero 145 and, more recently, decreased IL-21 production by CD4 + follicular helper T cells 146 have all been proposed to contribute to the high rate of HBV persistence but have not yet been confirmed in humans. In contrast to HBV, HCV causes most chronic infections by horizontal transmission between immunocompetent adults. A key factor in the development of HCV persistence is the emergence of viral escape mutations, which are selected not just in individual patients 14, 16 but in entire populations, resulting in patterns ('footprints') of mutations within or near virus-encoded T cell epitopes depending on the prevalent HLA haplotypes 15, 36 . If HCV is transmitted to an individual who has the respective HLA alleles, it does not stimulate T cell responses against the mutated epitopes, thereby increasing the likelihood of chronic infection. A second factor is decreased help by virus-specific CD4 + T cells, which has been reported not only for HCV infection 147 but also for HBV infection 148 and is associated with reduced function 18, 149, 150 and breadth 148 of the virus-specific CD8 + T cell response. Consistent with this finding, in vivo depletion of CD4 + T cells from chimpanzees that had recovered from HCV infection abrogated protective CD8 + T cell-mediated immunity upon HCV rechallenge 20 . Likewise, CD4 + T cell-depleted chimpanzees developed persistent HBV infection when inoculated with a dose of HBV that is typically cleared 151 .
The role of innate immune responses in the outcome of acute HBV and HCV infection is less clear. HBV remains at low to undetectable levels in the circulation for weeks after infection and does not stimulate proinflammatory cytokines or ISGs during this period in patients 152 and experimentally infected chimpanzees 153 . Recent studies in mouse models where HBV replication is launched from a recombinant adenovirus demonstrated that NKT cell activation by HBV-induced self lipids contribute to adaptive immune responses 154 , but it remains unknown whether the same occurs in patients.
For HCV, the outcome of infection has been linked to several single nucleotidepolymorphisms within or near IFNL genes 99, 155 , but the underlying immunological mechanisms are largely unknown. Whereas NKT and NK cells are activated in the early phase of infection along with the induction of ISGs, HCV has developed sophisticated means to escape from innate immune responses (reviewed in ref. 2) , and a notable decrease in HCV titer occurs only weeks later, when IFN-γ-producing CD8 + T cells appear in the liver 110,156 . npg r e v i e w suppression. Consistent with this notion, T cell responses against new HCV epitopes are rare in patients with chronic hepatitis C 67 , whereas the induction of T cell responses against unrelated immunogens is not impaired. Consistent with this observation, attempts to induce hepatitis virus-specific immune responses via vaccination have failed not only for chronic hepatitis C but also for chronic hepatitis B.
Collectively, these findings demonstrate that virus-specific T cell responses that are qualitatively or quantitatively insufficient to clear the virus in the acute phase of hepatitis B and C infection are downregulated in frequency and function in the chronic phase. Indeed, once chronic hepatitis is established, the antiviral effect of these remaining virus-specific CD8 + T cells is negligible, and these cells rarely select HCV escape mutations in the chimpanzee model 68 . Accordingly, experimental in vivo depletion of CD8 + T cells affects neither alanine aminotransferase (ALT) levels nor viremia in chronically HCVinfected chimpanzees (C. Walker, Nationwide Children's Hospital and Ohio State University College of Medicine, personal communication), whereas the absence of CD8 + T cells in acute HCV infection reduces liver injury and prevents viral clearance 5 . Thus, the benefit of downregulating virus-specific CD8 + T cell responses in the chronic phase of hepatitis may lie in the prevention of immunopathology, which is amplified by secondarily recruited mononuclear cells (Box 3).
In contrast to the detailed knowledge on CD8 + T cell responses in chronic hepatitis, much less is known about the downregulation of CD4 + T cell responses. Although antigen persistence has been implicated in causing CD4 + T cell dysfunction, CD4 + T cell function is only partially reversible by PD-1 and/or PD-L1 blockade or by antigen removal in mouse models 69, 70 . Furthermore, CD4 + T cell-driven immune escape is not an essential factor in the chimpanzee model of chronic HCV infection 71 . Recent studies have now identified a role of natural killer (NK) cells in the direct regulation of CD4 + and indirect regulation of CD8 + T cell responses in viral hepatitis, as described below. This regulatory activity of NK cells against CD4 + T cells in particular may account for the antigen-specific nature of defective T cell immunity in viral hepatitis-which, to date, has been difficult to explain mechanistically because hepatitis viruses such as HBV, HCV and LCMV do not infect T cells.
NK cell function in chronic viral hepatitis NK cells account for the majority of innate immune cells in the healthy human liver 72 , and their frequency is even higher in the liver and lower in the blood in chronic HBV and HCV infection [73] [74] [75] Peripheral blood NK cells from HBV-infected individuals express higher levels of the activating receptors NKp30, NKp46 and NKG2C 79 and lower levels of the inhibitory marker NKG2A 73, 79 than those from HCVinfected patients, but NK cells from HCV-infected patients also express higher levels of several activating receptors, such as NKp30 (ref. 80 
Box 3 Contribution of secondarily recruited mononuclear cells to disease pathogenesis
The emergence of viral escape mutations and the downregulation of T cell responses against conserved viral epitopes during chronic infection suggest that virus-specific T cells are not the major mediators of liver disease. Indeed, most of the necroinflammatory liver disease is due to secondarily recruited mononuclear cells (Fig. 4) . This is supported by the observation that patients chronically infected with HBV with and without liver inflammation do not differ in the frequency of intrahepatic HBV-specific CD8 + T cells but do differ in the size of the nonspecific mononuclear cell infiltrate 157 . Much has been learned from transgenic mice that express HBsAg or that replicate the complete HBV genome in their hepatocytes and are intravenously injected with HBs-specific CD8 + T cells (reviewed in ref. 1). The injected T cells travel via the portal vein into the liver sinusoids, where the slow blood flow and trapping by liver-resident macrophages (Kupffer cells) exposes them LSECs and, through fenestrae in the LSEC layer, to hepatocytes. Recognition of their cognate antigen triggers cytotoxicity and IFN-γ release 101 . IFN-γ blocks the assembly of HBV nucleocapsids and destabilizes HBV RNA 103, 104 . IFN-γ also activates macrophages and Kupffer cells to produce TNF-α and more IFN-γ 101 , which stimulates hepatocytes, stellate cells and LSECs to produce the chemokines CXCL9, CXCL10 and CXCL11. Hepatocyte-derived chemokines are then transported via transcytosis from the basolateral to the luminal surface of the endothelium and are expressed on LSECs (reviewed in ref. 158) . Combined with CCL3, CCL5, CXCL1, CXCL2, CXCL3 and CXCL5, which are produced by the portal tract vascular endothelium, and IL-1β, IL-6, IL-8, TNF-α and other cytokines from hepatocytes and IFN-γ-activated monocytes and macrophages, they recruit mononuclear cells (reviewed in ref. 159) . Their entry into the liver parenchyma is facilitated by neutrophil-derived matrix metalloproteinases, which remodel the extracellular matrix 137 . Activated platelets, which are detectable in intrahepatic necroinflammatory foci as well as in hepatic sinusoids, also contribute to chronic liver injury by facilitating lymphocyte entry 135 .
In the HBV mouse model, the recruitment of mononuclear cells can be prevented by depletion of neutrophils 138 , blocking of matrix metalloproteinases 137 or neutralization of chemokines 136 . All three measures reduce liver disease while maintaining the antiviral activity of HBV-specific CD8 + T cells. The secondarily recruited mononuclear cells therefore contribute to the liver injury but not to viral clearance. Inflammatory liver injury is perpetuated into chronic disease and, ultimately, hepatocellular carcinoma if a continued supply of HBs-specific CD8 + T cells is provided 139 .
The results from this animal model are relevant for viral hepatitis in humans. For example, serum IFN-α, IL-8, CXCL9 and CXCL10 concentrations 31, 160, 161 , rather than the frequency or effector functions of HBV-specific CD8 + T cells 160, 162 , increase during flares of chronic hepatitis B, suggesting that the increase in disease activity is due to an amplification of the intrahepatic lymphocyte infiltrate. Correlations between the serum levels of several chemokines and liver inflammation have also been observed in HCV-infected patients 163, 164 and are consistent with chemokine-mediated recruitment of T cells to the liver, even though one chemokine (CXCL10) has been shown to exist in a nonfunctional form 165 . npg r e v i e w the expression of CD69 (refs. 74,81), an inducible cell surface glycoprotein acquired during lymphoid activation. Intrahepatic NK cells are more activated than their counterparts in the peripheral blood 74, 80, 81 .
Unexpectedly, NK cell activation does not induce all effector functions to an equal degree. Whereas correlates of cytotoxicity such as degranulation and TNF-related apoptosis-inducing ligand (TRAIL) expression are increased in chronic HBV and HCV infection 74, 81 , IFN-γ and TNF-α production is suppressed 61, 74, 75, 81, 83 . This divergent functional phenotype has been attributed to chronic exposure to cytokines. In HBV infection, the selective defect in NK cell function is induced by IL-10 and TGF-β and can be restored upon in vitro blockade of these cytokines 61 . Although IL-10 is also present in the HCV-infected liver 34 , an additional causative factor is IFN-α 81 . IFN-α can be produced by human plasmacytoid dendritic cells 84 and Kupffer cells 85 that sense HCV RNA, whereas IFN-α and IFN-β induction and IFN-α/β receptor signaling are attenuated by HCV in infected hepatocytes (reviewed in ref. 2) . Chronic exposure of NK cells to endogenous IFN-α results in increased signal transducer and activator of transcription 1 (STAT1) expression levels and preferential STAT1 over STAT4 phosphorylation, as first described for NK cells from LCMV-infected mice 86, 87 and confirmed for NK cells from HCV-infected patients 88, 89 . This concomitant increase in pSTAT1-dependent cytotoxicity and decrease in pSTAT4-dependent IFN-γ production of NK cells 81, 88 (Fig. 2) can be reproduced in vitro when primary NK cells of healthy uninfected blood donors are stimulated with IFN-α 81 and is further enhanced when patients with chronic HCV infection undergo IFN-α-based therapy 88, 90 . Within hours after therapy initiation, NK cell degranulation and TRAIL production peak, concomitantly with a slight rise in serum ALT levels, whereas IFN-γ production decreases 88, 90 . These events correlate with STAT1 phosphorylation and reduction in HCV titer during the first 48 h of therapy, which mark the first phase of the virological response 88 . Thus, NK cells from individuals with rapid first-phase HCV RNA decline show maximal pSTAT1 induction in vivo and are refractory to further IFN-α stimulation in vitro. In contrast, NK cells from individuals with slow first-phase HCV RNA decline have markedly lower pSTAT1 levels and retain their in vitro responsiveness to IFN-α 88 . This is consistent with differential NK cell phenotype and function in treatment responders and nonresponders at later time points 90, 91 . Specifically, treatment responders show greater levels of NK cell degranulation than nonresponders for at least the first 12 weeks of IFN-based therapy 88 , the period that defines an early virological response. Patients with a sustained virological response also show enhanced NK cytotoxicity 92 . Thus, NK cell responses can be used as an indicator of a patient's IFN responsiveness, which, along with the expression level of interferon-stimulated genes (ISGs) [93] [94] [95] and IFNL single nucleotide polymorphisms [96] [97] [98] [99] , predict the treatment response. Specifically, high pretreatment ISG levels combined with low inducibility during treatment predict a poor virological response, whereas low pretreatment ISG levels combined with strong inducibility during treatment predict treatment success [93] [94] [95] . Likewise, high pretreatment levels of the inhibitory NKG2A and KIR3DL1 receptors on NK cells predict treatment failure 100 . Such NKG2A + NK cells concurrently express higher levels of the activation marker NKp44 before treatment than do NKG2A − NK cells, and they produce less CXCL10 and TRAIL upon in vitro IFN-α stimulation 100 . Thus, the responsiveness of NK cells to interferon-based therapy parallels the virological response and recapitulates what has been reported for ISGs 93, 95 .
Antiviral versus regulatory role of NK cells in viral hepatitis
The decreased ability of NK cells to produce IFN-γ probably reduces their antiviral function, because both HBV and HCV are sensitive to 88, 89 , resulting in increased cytotoxicity rather than IFN-γ production by NK cells in HCV-infected patients 74, 81 and LCMVinfected mice 86, 87 . In HBV infection, increased NK cell cytotoxicity has been attributed to IL-10 and TGF-β exposure 61 . NK cells kill activated CD4 + T cells in a perforin-dependent manner, which results in reduced CD4 + help to CD8 + T cells and exhaustion of the LCMV-specific T cell response after high-dose LCMV infection 120 (1) . Additional mechanisms of CD8 + T cell regulation include perforin-mediated lysis of activated CD8 + T cells that upregulate NKG2D in response to IL-10 in the LCMV model 122, 123 and TRAIL-mediated lysis of activated CD8 + T cells that express TRAIL-R2 in HBV infection 124 . CD8 + T cells can upregulate CD48 to engage the inhibitory NK cell receptor CD244 as a negative-feedback mechanism (2). NK cells also lyse human hepatocytes in HBV infection 31 (3) as well as activated human and mouse stellate cells with altered expression of activatory and inhibitory NK cell ligands (4).
npg r e v i e w this cytokine. For HBV, important information on the antiviral role of IFN-γ has been forthcoming from mouse models where IFN-γ from adoptively transferred HBV-specific CD8 + T cells 101 and from IL-12-activated NK cells downregulates HBV replication 102 . The molecular mechanisms of this antiviral effect have been identified in the same model 103, 104 . For HCV, the antiviral effect of IFN-γ has been demonstrated in hepatoma cell lines that harbor subgenomic HCV replicons 105 . This concept is supported by the observation that the initial decrease in HBV and HCV titer in infected patients and nonhuman primates coincides with the increase of IFN-γ and CD8 + mRNA in the liver 106, 107 and with the appearance of IFN-γ-secreting virus-specific T cells in both blood and liver [108] [109] [110] . HBV titers typically decline before maximal ALT elevation in acute hepatitis 106, 108, 109 , which supports the notion of cytokine-mediated antiviral effects by CD8 + T cells. However, HBV titers do not decrease at earlier time points when the frequency of NK cells increases in the blood 111 . In fact, NK cell activation and IFN-γ production are reduced during peak viremia in prospectively studied patients with acute hepatitis B 112 . Thus, NK cells, although activated, are unable to clear the infection on their own. Whether this is a general feature of human NK cells or the result of viral escape is not clear. The effect of HBV on NK cells has not been examined, and the effect of HCV has only been analyzed in vitro with tissue culture-derived virus. In these studies, human NK cells maintained their function if exposed to infectious HCV 113 , unless the HCV virions were coated on tissue culture plates, which increases their ability to crosslink CD81 (ref. 114) . Further in vitro studies demonstrated that HCV NS5A-induced IL-10 and TGF-β (ref. 115 ) and direct interaction between human NK cells and HCV-infected hepatoma cells 116 downregulate NK cell NKG2D expression and effector function. If these mechanisms extend to the interaction between NK cells and infected hepatocytes in the liver, NK cell-mediated elimination of virus-infected hepatocytes may be impaired. However, the sole study comparing NK cells in livers of HCV-infected patients and healthy controls reported that a potential inhibitory effect of the virus on intrahepatic NK cells must be transient rather than pervasive because these intrahepatic NK cells maintained their cytotoxic response to in vitro stimulation with inflammatory cytokines such as IFN-α (ref. 80) .
If NK cells fail to clear the virus, why is there no overall downregulation of NK cell cytotoxicity in both blood and liver, as reported for T cells? Recent studies in the LCMV model suggest that NK cell cytotoxicity fulfills an important regulatory role, namely the control of the inflammatory cascade that virus-specific CD4 + and CD8 + T cells initiate, as well as the fibrogenesis that stellate cells drive. As in HBV and HCV infection, NK cells do not seem to have a direct antiviral effect in LCMV infection 117 , yet they maintain their cytotoxic effector function (reviewed in ref. 118) . In a seminal report, NK cell cytotoxicity was shown to be beneficial to LCMV and the host after high-dose LCMV infection, because NK cell-mediated killing of activated CD4 + T cells eliminates help for CD8 + T cells 119 (Fig. 2) , which results in CD8 + T cell exhaustion, allowing LCMV to persist and the host to survive with minimal immunopathology (Fig. 3a) . CD4 + T cells are predominantly targeted, because CD8 + T cells express higher levels of CD48, which engages the inhibitory receptor CD244 on NK cells 120 (Fig. 2) . There are also conditions such as medium-dose LCMV infection, in which NK cell cytotoxicity is not beneficial because this viral dose does not drive CD8 + T cell exhaustion when NK cells eliminate CD4 + T cell help, resulting in viral persistence and extensive immunopathology (Fig. 3a) . In this condition, the virus-specific CD8 + T cell response is stronger in the absence than in the presence of NK cells and clears LCMV before the development of enhanced immunopathology by secondarily recruited mononuclear cells (Fig. 3a) . Finally, at low-dose LCMV infection, NK cells do not affect viral persistence and immunopathology because the virus is cleared in the presence or absence of NK cells. Thus, it has been suggested that NK cells function as 'rheostats' for virus-specific T cell responses 119 and that therapeutic targeting of NK cells may have differential effects based on the degree of virus-driven T cell exhaustion (Fig. 3b) .
NK cells have also been shown to indirectly regulate CD8 + T cell function in the LCMV model through effects on antigenpresenting cells 121 . Although the specific mechanism of this pathway is still unclear, it does not seem to be an antiviral effect because the initial level of viremia and the number of antigen-presenting cells and their expression of co-stimulatory or inhibitory molecules are not affected. Rather, by an unknown mechanism, NK cells limit the ability of antigen-presenting cells to stimulate CD8 + T cell proliferation 121 . In addition to the indirect regulation of CD8 + T cell function, NK cells can directly lyse in a perforin-mediated manner CD8 + T cells that upregulate NKG2D ligands in LCMVinfected mice 122, 123 (Fig. 2) . Consequently, NK cell depletion or npg r e v i e w NKG2D blockade increases the frequency of functional antigenspecific CD8 + T cells in this model 122 .
The NK cell-mediated regulation of virus-specific T cell responses is supported by recent translational studies in HBV-infected patients, in whom in vitro depletion of NK cells from peripheral blood mononuclear cells of HBV-infected patients increased HBV-but not cytomegalovirus-specific CD8 + T cell responses 124 . The specificity of the NK cell response was attributed to a higher proportion of HBV-specific compared to cytomegalovirus-specific CD8 + T cells expressing TRAIL death receptor 2 (TRAIL-R2), which rendered them susceptible to apoptosis by TRAIL-expressing NK cells. Increased TRAIL-R2 expression was specifically observed on intrahepatic HBV-specific CD8 + T cells in close contact with TRAIL-expressing NK cells, and it correlated with HBV titer 124 . This regulatory role of NK cells may be relevant during HBV flares. HBV-infected patients who develop flares typically develop increased HBV viremia and HBV antigen levels, followed by increased serum IFN-α, IL-8 (ref. 31 ) and ALT concentrations. IFN-α can contribute to the observed increased TRAIL expression by NK cells during HBV flares 31 , and the concomitant increase in IL-8 levels can promote the recruitment of activated NK cells to the liver and the induction of TRAIL-R2 on intrahepatic T cells (Fig. 2) . Thus, NK cells may contribute to the control of intrahepatic CD8 + T cell responses during the flare. These CD8 + T cell responses can be enhanced because flareassociated increases in the production of inflammatory cytokines, such as that of IL-12 by activated Kupffer cells and IL-15 by LSECs, render human T cells more susceptible to T cell receptor-mediated signals and enhance their effector functions 125 .
Finally, NK cell-mediated cytotoxicity may also contribute to the control of stellate cells, which drive liver fibrosis. Stellate cells are located in the space of Dissé in close contact with NK cells (Fig. 4) , store most of the body's vitamin A and are the primary source of type I and III collagen (reviewed in ref. 126 ). Collagen production requires stellate cell activation, which is triggered by cytokines, reactive oxygen species, phagocysis and Toll-like receptor 9-mediated recognition of DNA from apoptotic hepatocytes (reviewed in ref. 127) . Upon activation, stellate cells differentiate into myelofibroblastic cells and convert vitamin A into retinoic acid, which induces the activating NK cell ligand RAE1 in mouse models of liver fibrosis (Fig. 2) 128 Inflam m a t io n and re g e n e ra tion Figure 4 Pathogenesis of HBV-related liver disease. Simplified schematic presentation of key immunological factors that contribute to the pathogenesis of acute and chronic liver disease. As described in Box 3, these findings are mostly based on observations made in transgenic mice that express HBV surface antigen (HBsAg) or that replicate the complete HBV genome in their hepatocytes and were reconstituted with HBs-specific CD8 + T cells 101, 103, [134] [135] [136] [137] [138] [139] . DC, dendritic cell; HSC, hematopoietic stem cell; ICAM, intracellular adhesion molecule; Mϕ macrophage; MMP, matrix metalloproteinase; T reg , regulatory T cell; VCAM, vascular cell adhesion molecule.
npg r e v i e w class I 129 and upregulate TRAIL receptors 130 , which converts the cells into targets for NKG2D-, TRAIL-and granzyme-mediated killing by NK cells 128, 129 . NKG2D-and TRAIL-mediated killing of stellate cells has also been shown for NK cells from HCV-infected patients 131 , and NKp46 + NK cells have been shown to accumulate in the liver of HCV-infected patients and to lyse human stellate cells in vitro (Fig. 2) 132 . Accordingly, the absence of either NK cells 128, 129 or the mouse ortholog of the NKp46 receptor 133 enhances liver fibrosis in mouse models. Collectively, these studies suggest that preservation of NK cell cytotoxicity serves a nonclassical regulatory rather than a classical antiviral role in viral hepatitis.
Conclusion
CD4 + and CD8 + T cell responses play a unique part in HBV and HCV infection because they contribute not only to viral clearance and protective immunity in those who recover from infection but also to considerable liver injury. If the viruses cannot be cleared and chronic infection ensues, responses by virus-specific T cells and by secondarily recruited mononuclear cells need to be tightly controlled. The induction of inhibitory molecules such as PD-1, CTLA-4 and Tim-3 on T cells and their ligands in the liver, the production of immunosuppressive cytokines such as IL-10 and TGF-β, and the recently discovered regulatory role of NK cells allow the host to counteract liver inflammation and disease progression. Importantly, these mechanisms target virus-specific immune responses and, thus, do not result in global immune suppression. These findings have therapeutic implications, because all treatment strategies to date are aimed at elimination of the virus, either via antiviral drugs, which are still problematic for chronic HBV infection, or enhancement of antiviral immune responses, which has the potential of inducing significant immunopathology. A better understanding of the endogenous mechanisms that regulate liver inflammation and disease pathogenesis may help us to determine why liver disease progresses more rapidly in some patients than in others. At the same time, it may result in new therapeutic treatment options to decrease the rate of disease progression in viral infections that cannot be cleared with antiviral agents.
